Antibody-Drug Conjugate (ADC): A targeted cancer therapy that combines an antibody with a cytotoxic drug, allowing for the delivery of the drug directly to cancer cells. HER2-positive: A ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...

Huang, B.T., Li, K.F., Wu, X.S., Zhang, F.Y. and Li, Y.P. (2025) Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12.89 billion in 2025 to USD 25.38 billion by 2033, growing at a CAGR of 8.84 ...

Dr Suchitra Sundaram recalls a patient she treated over a decade ago and discusses how recent advances in targeted therapies have reshaped treatment strategies.

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC ... is a potential best-in-class ADC for the treatment of GI malignancies based on preclinical ...